Most Recent Articles by Bryant Furlow
"CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses," according to Dr Michel Sadelin.
Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple MyelomaDec 12, 2018
XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.
Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.
EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.
The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.
More Articles by Bryant Furlow
Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer CentersNov 15,2018
Researchers Use Artificial Intelligence to Predict Patient Survival from Pathology Images in Lung CancerAug 28,2018
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- Lower-Dose, Shorter-Duration Chemotherapy Regimens: Is This a Trend?
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis